45.42 USD
-1.74 (-3.69%)
45.42 USD
0 (0%)
Overall SUPN gets a fundamental rating of 5 out of 10. We evaluated SUPN against 191 industry peers in the Pharmaceuticals industry. SUPN has an average financial health and profitability rating. SUPN has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
In the past year SUPN was profitable.
In the past year SUPN had a positive cash flow from operations.
Each year in the past 5 years SUPN has been profitable.
SUPN had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
The Return On Assets of SUPN (-1.35%) is better than 74.87% of its industry peers.
SUPN has a Return On Equity of -1.82%. This is in the better half of the industry: SUPN outperforms 77.49% of its industry peers.
SUPN has a better Return On Invested Capital (2.34%) than 79.58% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for SUPN is significantly below the industry average of 12.85%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.35% | ||
| ROE | -1.82% | ||
| ROIC | 2.34% |
ROA(3y)3.02%
ROA(5y)4.13%
ROE(3y)4.71%
ROE(5y)7.54%
ROIC(3y)2.7%
ROIC(5y)4.37%
1.3 Margins
In the last couple of years the Profit Margin of SUPN has declined.
The Operating Margin of SUPN (6.08%) is better than 79.58% of its industry peers.
In the last couple of years the Operating Margin of SUPN has declined.
The Gross Margin of SUPN (89.91%) is better than 92.15% of its industry peers.
SUPN's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 6.08% | ||
| PM (TTM) | N/A | ||
| GM | 89.91% |
OM growth 3Y-9.85%
OM growth 5Y-18.4%
PM growth 3Y6.61%
PM growth 5Y-17.27%
GM growth 3Y0.96%
GM growth 5Y-1.32%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so SUPN is destroying value.
SUPN has more shares outstanding than it did 1 year ago.
The number of shares outstanding for SUPN has been increased compared to 5 years ago.
There is no outstanding debt for SUPN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
SUPN has an Altman-Z score of 5.70. This indicates that SUPN is financially healthy and has little risk of bankruptcy at the moment.
With a decent Altman-Z score value of 5.70, SUPN is doing good in the industry, outperforming 77.49% of the companies in the same industry.
There is no outstanding debt for SUPN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 5.7 |
ROIC/WACC0.25
WACC9.19%
2.3 Liquidity
SUPN has a Current Ratio of 1.80. This is a normal value and indicates that SUPN is financially healthy and should not expect problems in meeting its short term obligations.
SUPN has a Current ratio of 1.80. This is in the lower half of the industry: SUPN underperforms 64.40% of its industry peers.
SUPN has a Quick Ratio of 1.56. This is a normal value and indicates that SUPN is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of SUPN (1.56) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.8 | ||
| Quick Ratio | 1.56 |
3. Growth
3.1 Past
The Earnings Per Share has been growing slightly by 0.32% over the past year.
The Earnings Per Share has been growing slightly by 6.93% on average over the past years.
SUPN shows a small growth in Revenue. In the last year, the Revenue has grown by 4.54%.
Measured over the past years, SUPN shows a quite strong growth in Revenue. The Revenue has been growing by 11.00% on average per year.
EPS 1Y (TTM)0.32%
EPS 3Y44.39%
EPS 5Y6.93%
EPS Q2Q%-13.68%
Revenue 1Y (TTM)4.54%
Revenue growth 3Y4.51%
Revenue growth 5Y11%
Sales Q2Q%9.34%
3.2 Future
The Earnings Per Share is expected to grow by 19.52% on average over the next years. This is quite good.
Based on estimates for the next years, SUPN will show a quite strong growth in Revenue. The Revenue will grow by 14.90% on average per year.
EPS Next Y-3.99%
EPS Next 2Y12.49%
EPS Next 3Y17.74%
EPS Next 5Y19.52%
Revenue Next Year9.32%
Revenue Next 2Y16.13%
Revenue Next 3Y15.71%
Revenue Next 5Y14.9%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 14.65 indicates a correct valuation of SUPN.
Based on the Price/Earnings ratio, SUPN is valued cheaper than 86.39% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 26.34. SUPN is valued slightly cheaper when compared to this.
With a Price/Forward Earnings ratio of 12.17, SUPN is valued correctly.
Based on the Price/Forward Earnings ratio, SUPN is valued cheaper than 83.25% of the companies in the same industry.
SUPN is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 23.56, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 14.65 | ||
| Fwd PE | 12.17 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, SUPN is valued a bit cheaper than the industry average as 79.58% of the companies are valued more expensively.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of SUPN indicates a somewhat cheap valuation: SUPN is cheaper than 78.53% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 36.81 | ||
| EV/EBITDA | 18.08 |
4.3 Compensation for Growth
A more expensive valuation may be justified as SUPN's earnings are expected to grow with 17.74% in the coming years.
PEG (NY)N/A
PEG (5Y)2.11
EPS Next 2Y12.49%
EPS Next 3Y17.74%
5. Dividend
5.1 Amount
No dividends for SUPN!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
45.42
-1.74 (-3.69%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners104.09%
Inst Owner Change-3.26%
Ins Owners4.25%
Ins Owner Change2.79%
Market Cap2.60B
Revenue(TTM)681.54M
Net Income(TTM)-19.12M
Analysts83.33
Price Target61.71 (35.87%)
Short Float %9.48%
Short Ratio5.88
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)77.78%
Min EPS beat(2)67.83%
Max EPS beat(2)87.73%
EPS beat(4)4
Avg EPS beat(4)62.07%
Min EPS beat(4)15.55%
Max EPS beat(4)87.73%
EPS beat(8)7
Avg EPS beat(8)65.74%
EPS beat(12)9
Avg EPS beat(12)51.6%
EPS beat(16)10
Avg EPS beat(16)29.18%
Revenue beat(2)2
Avg Revenue beat(2)5.28%
Min Revenue beat(2)5.28%
Max Revenue beat(2)5.29%
Revenue beat(4)3
Avg Revenue beat(4)4.96%
Min Revenue beat(4)-0.71%
Max Revenue beat(4)9.98%
Revenue beat(8)6
Avg Revenue beat(8)5.09%
Revenue beat(12)8
Avg Revenue beat(12)3.15%
Revenue beat(16)11
Avg Revenue beat(16)2.6%
PT rev (1m)3.95%
PT rev (3m)38.13%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-56.74%
EPS NY rev (1m)4.91%
EPS NY rev (3m)30.98%
Revenue NQ rev (1m)-1.64%
Revenue NQ rev (3m)-1.53%
Revenue NY rev (1m)0.03%
Revenue NY rev (3m)3.32%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 14.65 | ||
| Fwd PE | 12.17 | ||
| P/S | 3.82 | ||
| P/FCF | 36.81 | ||
| P/OCF | 36.23 | ||
| P/B | 2.48 | ||
| P/tB | 8.48 | ||
| EV/EBITDA | 18.08 |
EPS(TTM)3.1
EY6.83%
EPS(NY)3.73
Fwd EY8.22%
FCF(TTM)1.23
FCFY2.72%
OCF(TTM)1.25
OCFY2.76%
SpS11.89
BVpS18.31
TBVpS5.36
PEG (NY)N/A
PEG (5Y)2.11
Graham Number35.73
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.35% | ||
| ROE | -1.82% | ||
| ROCE | 3.81% | ||
| ROIC | 2.34% | ||
| ROICexc | 3.16% | ||
| ROICexgc | 38.99% | ||
| OM | 6.08% | ||
| PM (TTM) | N/A | ||
| GM | 89.91% | ||
| FCFM | 10.38% |
ROA(3y)3.02%
ROA(5y)4.13%
ROE(3y)4.71%
ROE(5y)7.54%
ROIC(3y)2.7%
ROIC(5y)4.37%
ROICexc(3y)4.39%
ROICexc(5y)6.6%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)4.82%
ROCE(5y)7.36%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3Y11.61%
ROICexc growth 5Y-8.56%
OM growth 3Y-9.85%
OM growth 5Y-18.4%
PM growth 3Y6.61%
PM growth 5Y-17.27%
GM growth 3Y0.96%
GM growth 5Y-1.32%
F-Score4
Asset Turnover0.48
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 1.32% | ||
| Cap/Sales | 0.16% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 56.66% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.8 | ||
| Quick Ratio | 1.56 | ||
| Altman-Z | 5.7 |
F-Score4
WACC9.19%
ROIC/WACC0.25
Cap/Depr(3y)0.67%
Cap/Depr(5y)5.39%
Cap/Sales(3y)0.09%
Cap/Sales(5y)0.25%
Profit Quality(3y)2940.94%
Profit Quality(5y)1832.68%
High Growth Momentum
Growth
EPS 1Y (TTM)0.32%
EPS 3Y44.39%
EPS 5Y6.93%
EPS Q2Q%-13.68%
EPS Next Y-3.99%
EPS Next 2Y12.49%
EPS Next 3Y17.74%
EPS Next 5Y19.52%
Revenue 1Y (TTM)4.54%
Revenue growth 3Y4.51%
Revenue growth 5Y11%
Sales Q2Q%9.34%
Revenue Next Year9.32%
Revenue Next 2Y16.13%
Revenue Next 3Y15.71%
Revenue Next 5Y14.9%
EBIT growth 1Y-47.81%
EBIT growth 3Y-5.79%
EBIT growth 5Y-9.43%
EBIT Next Year10.08%
EBIT Next 3Y40.06%
EBIT Next 5Y32.85%
FCF growth 1Y-23.92%
FCF growth 3Y11.03%
FCF growth 5Y4.05%
OCF growth 1Y-23.21%
OCF growth 3Y10.6%
OCF growth 5Y3.74%
SUPERNUS PHARMACEUTICALS INC / SUPN FAQ
Can you provide the ChartMill fundamental rating for SUPERNUS PHARMACEUTICALS INC?
ChartMill assigns a fundamental rating of 5 / 10 to SUPN.
Can you provide the valuation status for SUPERNUS PHARMACEUTICALS INC?
ChartMill assigns a valuation rating of 5 / 10 to SUPERNUS PHARMACEUTICALS INC (SUPN). This can be considered as Fairly Valued.
What is the profitability of SUPN stock?
SUPERNUS PHARMACEUTICALS INC (SUPN) has a profitability rating of 5 / 10.
What is the valuation of SUPERNUS PHARMACEUTICALS INC based on its PE and PB ratios?
The Price/Earnings (PE) ratio for SUPERNUS PHARMACEUTICALS INC (SUPN) is 14.65 and the Price/Book (PB) ratio is 2.48.
How financially healthy is SUPERNUS PHARMACEUTICALS INC?
The financial health rating of SUPERNUS PHARMACEUTICALS INC (SUPN) is 6 / 10.